Many patients with cystic fibrosis (CF) now reach adulthood, at which time the risk of cancer is increased. The aim of this study was to determine cancer risks in nontransplanted and transplanted CF patients.
Cystic fibrosis (CF), the most common lethal genetic disorder in Caucasians, affects approximately 30 000 children and adults in the United States and an estimated 70 000 individuals worldwide (1) . It is caused by a recessive genetic defect of the cystic fibrosis transmembrane conductance regulator (CFTR) gene that leads to dehydrated secretions primarily affecting the respiratory, digestive, and reproductive systems.
Because of advances in disease management, many CF patients now reach adulthood, when the likelihood of developing cancer is increased. Abdul-Karim et al. (2) described the first CF patient with cancer in 1982, an adult with an extra-hepatic biliary tract cancer. Subsequent studies have shown an increased risk of digestive tract cancers among CF patients that is enhanced after transplantation (3) (4) (5) (6) .
The aim of this study was to confirm and extend previous findings about the risk of cancer in CF patients, using data obtained prospectively over a 20-year period from the US Cystic Fibrosis Foundation (CFF) Patient Registry.
Additional aims were to determine if there was an excess of tumors, such as leukemia, that have previously been associated with exposure to radiation and to determine if the risk of cancer varies according to individual patient attributes. Such information could identify patients at higher risk of developing cancer who might benefit from screening.
Methods

Study Population
The cohort consisted of all 41,188 CF patients free of cancer at start of follow-up who were reported to the CFF Patient Registry and followed at least once during the period from 1990 to 2009 at any of the 250 CF care center programs within the 110 accredited CF care centers in the United States. Details on data collection, genotype coding, and identification of cancer cases are given in the Supplementary Materials (available online). The study protocol was approved by the CFF Registry Committee and the institutional review boards of the European Institute of Oncology and New York Medical College. Written informed consent was obtained from all participants.
Statistical Analysis
The period during which patients in the nontransplant group were at risk was defined as the time from 1990 to first cancer, death, transplant, or to the end of the calendar year in which a patient was last reported seen at a CF center. The time at risk for patients registered after 1990 began at that person's date of diagnosis with CF. To determine the risk of cancer in the transplant group, the risk period was defined as beginning at the date of lung or any other organ transplantation. Data on all persons alive and actively followed were censored as of December 31, 2009.
The number of cancers expected during the at-risk period was determined by applying age-(within 5-year groups), sex-, race-, and calendar year-specific incidence rates obtained from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute for the SEER nine registries (7) to the total person-years accumulated in the corresponding categories (see additional details in Supplementary Material, available online).
We used the standardized incidence ratio (SIR), defined as the ratio of the number of cancers observed to the number of cancers expected, to estimate the relative risk of cancer, and we calculated 95% confidence intervals (CIs) for the SIR assuming that the observed cases of cancer followed a Poisson distribution. The absolute excess risk was defined as the greater than expected number of new cancer cases (ie, number of cancers observed less the number of cancers expected) per 100,000 patients per year. Stratified analyses of the standardized incidence ratios by age, sex, genotype, or symptoms at diagnosis were performed. All analyses were carried out with the SAS software version 8.2 (Cary, NC). All statistical tests were two-sided, and P values less than.05 were considered statistically significant.
To minimize the possibility of discovering chance associations, we listed hypotheses in our initial study protocol. Some of these hypotheses were, however, generated or strengthened by our previous analysis based on the 1990 to 1999 data (5) . All the statistically significant associations that we report either confirm or extend results from previous reports.
results
Patients
Data from 41 188 CF patients over the 20-year period (52.2% males; 93.8% Caucasian) were available for the analysis. The proportion of patients diagnosed with CF during adulthood (≥18 years) increased over the study period from 6.3% during the period from 1990 to 1994 to 9.9% during the period from 2005 to 2009. At the end of 2009, there were 26 276 patients on follow-up in the registry, with a mean age of 19.0 years and with 12 323 patients (46.9%) aged greater than 18 years.
We classified 24 928 patients who had complete genotype information recorded according to the functional class of their mutations: 22,248 patients (89.2%) were categorized as having a severe genotype (ie, with two mutations from class I, II, or III), whereas 2680 patients (10.8%) had a mild genotype (ie, with one or two class IV or class V mutations). Table 1 presents the number of observed and expected cancers with corresponding standardized incidence ratio and 95% confidence intervals among nontransplanted CF patients separately for the period from 1990 to 1999 and for the period from 2000 to 2009. Because the overall distribution of cancers and site-specific risk estimates were similar during the two study periods, data were combined to increase statistical power, provide more robust risk estimates, and allow subgroup analyses. During 344,114 personyears of observation accumulated during the period from 1990 to 2009, 172 invasive cancers were reported in nontransplanted CF patients compared with 153.5 expected cancers (SIR = 1.1, 95% CI = 1.0 to 1.3) ( Table 2 ). Cancer cases were distributed uniformly throughout the country with no evidence of clustering (data not shown).
Cancer in Nontransplanted Patients
We found a statistically significant increase in digestive tract cancer (45 observed vs 12.8 expected; SIR = 3.5, 95% CI = 2.6 to 4.7). Thirty-one patients had a diagnosis of bowel cancer either in the colon (26 observed vs 4.2 expected; SIR = 6.2, 95% CI = 4.2 to 9.0) or small bowel (5 observed vs 0.4 expected; SIR = 11.5, 95% CI = 4.2 to 25.4). The SIR for bowel cancer was somewhat higher for men (22 observed vs 2.6 expected; SIR = 8.4, 95% CI = 5.4 to 12.4) than for women (9 observed vs 2.0 expected; SIR = 4.6, 95% CI = 2.2 to 8.3) but did not vary substantially according to age (Table 3 ). Bowel cancer risk was highest among patients classified as having severe genotype, particularly among those homozygous for the F508del mutation.
Bowel cancer risk was particularly elevated in patients previously reported to have had distal intestinal obstruction syndrome (9 observed vs 0.8 expected; SIR = 11.2, 95% CI = 5.5 to 20.5). On average, distal intestinal obstruction syndrome preceded the diagnosis of bowel cancer by 9 years, and in only one patient was the interval less than 5 years. Other prior gastrointestinal or other CF complications, such as CF-related diabetes, gallbladder disease, gastroesophageal reflux (GERD), liver disease, or nasal polyps, were not associated with a higher risk of developing bowel cancer.
There was an increase of biliary tract cancer (4 observed vs 0.4 expected; SIR = 11.4, 95% CI = 3.6 to 27.4). We also found an excess of cancer arising in the esophagus and in the stomach that became statistically significant for the two sites combined (5 observed vs 1.6 expected; SIR = 3.1, 95% CI = 1.1 to 6.8) but was not related to prior GERD ( Table 2) .
The increases of digestive tract cancer and colon cancer specifically were statistically significant for cases diagnosed during the period from 1990 to 1999 and for cases diagnosed during the period from 2000 to 2009 (Table 1) .
Among non-digestive tract cancer sites, we found a statistically significant increased or decreased risk of several cancers. We observed a decreased risk of melanoma (6 observed vs 14.7 expected; SIR = 0.4, 95% CI = 0.2 to 0.9) ( Table 2 ). The mean age at diagnosis was 40.2 years (range = 22 to 61 years). The decreased risk of melanoma was most notable in the subgroup of patients with a severe genotype (eg, patients homozygous for the F508del mutation) (Table 3) .
Sixteen patients had a diagnosis of testicular cancer at a mean age of 31.8 years (range = 19 to 48 years) vs 9.3 expected (SIR = 1.7, 95% CI = 1.02 to 2.7). The increase in testicular cancer was most notable in the subgroup of patients with a severe genotype (eg, patients homozygous for the F508del mutation: 11 observed vs 3.7 expected; SIR = 3.0, 95% CI = 1.6 to 5.2) ( Table 3) .
Seventeen patients had a diagnosis of lymphoid leukemia at a mean age of 22.5 years (range = 8 to 62 years) vs 8.0 expected (SIR = 2.0, 95% CI = 1.2 to 3.1). Fifteen (88.2%) had CF diagnosed before age 5 years, and in 13 of the 15 (76.5%) cancer was diagnosed before age 20 years. The increase in lymphoid leukemia was present to some degree in all subgroups studied (Table 3) .
We observed a decrease in respiratory tract cancers of borderline statistical significance (3 observed vs 7.4 expected; SIR = 0.4, 95% CI = 0.1 to 1.1) and a statistically nonsignificant excess of thyroid cancers (16 observed vs 10.6 expected; SIR = 1.5, 95% CI = 0.9 to 2.4) ( Table 2) .
Cancer in Transplanted CF Patients
We performed similar analysis in transplanted CF patients, presenting results obtained separately for the period from 1990 to 1999 and for the period from 2000 to 2009 in Table 4 and results obtained for the combined 20-year period in Table 5 .
During 8235 person-years of observation accumulated during the period from 1990 to 2009, 26 invasive cancers were reported in 2749 transplanted CF patients compared with 9.6 expected cancers (SIR = 2.7, 95% CI = 1.8 to 3.9) ( Table 5) . Of transplanted CF patients, 2749 (92.1%) received a lung transplant, 204 (7.4%) received a liver transplant, and 12 (0.4%) received another organ transplant. Twenty-four of the posttransplant cancers were in lung recipients, and two were in liver recipients.
As in nontransplanted CF patients, there was a statistically significant increase in the number of digestive tract cancers (19 observed vs 1.1 expected; SIR = 17.3, 95% CI = 10.7 to 26.5). This increase was statistically significant for cancer of the esophagus, small intestine, colon, biliary tract, and other digestive organs (Table 5 ). More post-transplant cancers were reported during the period from 2000 to 2009 than during the period from 1990 to 1999 because of the higher prevalence of transplanted CF patients during the later period, but standardized incidence ratios were similar during the two periods ( Table 4 ). The risk of bowel cancer following transplantation was higher in patients homozygous for the F508del mutation (data not shown) and in all the cases (n = 7) for which genotype was classified as severe.
Anatomical Location of Digestive Tract Cancers
Precise anatomical location of intestinal tumors was available for only a small number of the cases, but data showed a higher frequency of tumors in the right colon among nontransplanted and transplanted CF patients than in the general population (Supplementary Table 3 , available online).
The three cases of cancer attributed to the stomach were located at the cardio-esophageal junction, and the three cases of esophageal cancer (two following transplantation) for which we had detailed anatomic information were also located at the gastro-esophageal (or squamo-columnar) junction, with evidence of Barrett's esophagus in all cases. 
Discussion
This study is based on a large comprehensive database maintained by the CFF where cancer information has been routinely recorded since 1992. However, we contacted the individual care centers to confirm the presence of and obtain details about the type of cancer.
Because several hypotheses were generated from our previous report based on previously collected data from 1990 to 1999 (5), we first confirmed the findings using new data collected during the period from 2000 to 2009. Then we combined data for the two periods, providing the world's largest dataset ever explored for the association between CF and cancer. We confirmed the increased risk of digestive tract cancer and determined that digestive cancer is particularly likely to occur in certain anatomical sites, including the esophago-gastric junction, the small bowel, the colon, and the biliary tract. The risk is most notable in patients with a severe genotype and is markedly increased following transplantation. These associations are reasonable because GERD, inflammatory bowel disease, and sclerosing cholangitis, all risk factors for malignancy, are frequent conditions in children and adults with CF (8-11). Unfortunately we did not have data on inflammatory bowel disease or sclerosing cholangitis in our database to test for their association with digestive cancer risk in CF, and we did not confirm an association between GERD (reported as complication of CF) and gastro-esophageal cancer. Lung transplantation is, however, known to exacerbate GERD, and this could explain the higher risk of esophageal cancer that we observed in transplanted CF patients (12) . We do not have solid explanation for the association between distal intestinal obstruction syndrome and bowel cancer, but dysmotility and altered fecal microbiome may be contributing factors.
We also confirmed increased risks of cancer in several organs that were observed in our previous studies but were not statistically significant. There was a threefold increase in the risk of testicular cancer in patients homozygous for the F508del mutation. Although a genetic mechanism could not be excluded, this association may be attributed to infertility or testicular abnormalities, which are common features of CF, especially in patients with severe phenotype (13, 14) .
There are concerns about the possible risk of radiation-induced cancer in CF patients because, from childhood, they undergo multiple radiographic and computed tomography examinations. In particular, exposure to postnatal diagnostic x-rays has been associated with an increased risk of childhood acute lymphoblastic leukemia (15, 16) . We anticipated and confirmed an increase of acute lymphoblastic leukemia in CF patients, but the absolute increase remained very low (approximately 2 per 100,000 CF patients), particularly because CF is itself a life-threatening disease. We do not have individual radiation exposure information to confirm a dose-response relationship, but in both nontransplanted and transplanted patients, we found an excess of thyroid cancer, another tumor associated with radiation exposure. The excess in cases of thyroid cancer may, however, be because of increased surveillance of the CF population compared with the general population. It is also possible that some of the colon tumors in CF might be associated with excess radiation because in patients with inflammatory bowel disease, repeated exposure to x-ray (small bowel x-rays or barium enemas) has been shown to potentially increase the risk of colorectal neoplasia (10) .
We found a statistically significant decrease in the risk of melanoma in CF patients, extending and confirming several previous reports (17, 18) . This association, which is unlikely to be due to chance, is restricted to patients homozygous for the F508del mutation for whom the decrease in risk reaches 80%, suggesting a possible genetic protection of this mutation during melanomagenesis. The decreased risk of melanoma may also relate to the reduced time spent outdoors by children with CF (19) .
As in previous reports, the number of cancers of the head and neck, bone, breast, female reproductive organs, prostate, and eye and the number of lymphomas observed in the cohort was similar to that expected in the general US population of same age, sex, and race. There was a statistically nonsignificant decrease in cancer of the respiratory tract, bladder, and kidney, likely attributable to the low prevalence of smoking in the CF population. In 2010, the overall rate of tobacco smoke exposure, including secondhand smoke exposure, was 23.4% among the entire CF population (20) . The highest frequency of current smokers (7%) was reported among CF patients aged 18 to 24 years.
Overall, we found that the risk of solid cancer was increased at many sites following transplantation. The limited number of posttransplant cancer cases in our series does not allow us to make a thorough comparison with the pattern of both infection-related and unrelated cancers that is generally observed in non-CF solid organ transplant recipients (21) . The particularly high risk of bowel cancer that we depicted could result from the combination of the underlying bowel cancer risk and immunosuppression following lung transplantation (22) .
Our study has some limitations. Although we previously obtained complete information for the cases reported during the period from 1990 to 1999 (7), because of patient confidentiality issues and the switch to medical electronic records, case ascertainment was incomplete for the period from 2000 to 2009. We adjusted the analysis for the period from 2000 to 2009 to correct for the partial response; the results for the last decade are similar to our previous report based on complete data.
We relied solely on notification of cancer from CF care providers. It is, therefore, possible that some cases of cancer were never reported to the CFF Patient Registry or even known by CF care providers themselves. This is particularly true for post-transplant patients who may be followed-up at transplant centers rather than returning to the CF care centers. Therefore, any excess risk estimates are likely to be conservative, whereas decreased risk estimates for melanoma could result from underreporting.
We compared the number of cancers observed in the US CF population with that expected based on cancer incidence rates reported in the SEER 9 registries, which comprise only 10% of the total US population. It is, therefore, possible that some demographic, cultural, or socioeconomic differences between the SEER population and the total US population may have caused imprecision in our results (23) . Finally, we assumed that patients in the CFF Patient Registry are representative of the whole CF population. Only a small proportion (5% to 6 % across the nation) of patients who receive care at one of the CFF accredited care centers choose not to participate in the registry. The registry may, however, be less comprehensive for patients who undergo a lung transplantation because they often continue their ongoing care at the transplant center and do not return to the CF care center and for patients diagnosed in adulthood who already have established ongoing care with a pulmonologist and do not always shift their care to a CFF care center. Still, there is no reason to suspect that patients not in the registry would have an incidence of cancer that differs from those in the registry and included in our study.
In conclusion, our study provides epidemiological evidence of an increased risk of digestive tract cancer in CF patients, particularly following transplantation, as well as increased risks of lymphoid leukemia and testicular cancer and a decreased risk of melanoma. It also provides insights about potential mechanisms that may increase or decrease cancer risk in this population.
Because the absolute risk of cancer in CF remains low, systematic early screening may not be necessary for all CF patients. A better approach might be to selectively screen patients at higher risk, such as patients suffering from GERD, sclerosing cholangitis, or inflammatory bowel disease. Because of the extremely high risk of colon cancer in transplanted CF patients, screening colonoscopy should be strongly considered prior to transplantation (22) and periodically thereafter. 
